Equities

Aptamer Group PLC

APTA:LSE

Aptamer Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.925
  • Today's Change-0.025 / -2.63%
  • Shares traded2.75m
  • 1 Year change131.25%
  • Beta1.3287
Data delayed at least 20 minutes, as of Feb 06 2026 16:14 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Aptamer Group PLC grew revenues 39.88% from 860.00k to 1.20m while net income improved from a loss of 2.96m to a smaller loss of 2.42m.
Gross margin48.13%
Net profit margin-201.50%
Operating margin-211.06%
Return on assets-86.53%
Return on equity-213.66%
Return on investment-154.00%
More ▼

Cash flow in GBPView more

In 2025, Aptamer Group PLC increased its cash reserves by 21.72%, or 189.00k. Cash Flow from Financing totalled 2.23m or 184.95% of revenues. In addition the company used 1.94m for operations while cash used for investing totalled 92.00k.
Cash flow per share-0.0012
Price/Cash flow per share--
Book value per share0.0007
Tangible book value per share0.0006
More ▼

Balance sheet in GBPView more

Aptamer Group PLC has a Debt to Total Capital ratio of 26.22%, a lower figure than the previous year's 63.58%.
Current ratio1.55
Quick ratio1.48
Total debt/total equity0.3553
Total debt/total capital0.2622
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.